PACIRA BIOSCIENCES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Pacira BioSciences, Inc. - PCRX

Lawsuit Overview - Pacira BioSciences and certain executives are charged with failing to disclose material information during the Class Period, violating federal securities laws [3] - The lawsuit is pending in the United States District Court for the District of New Jersey [1] Key Events - On August 9, 2024, Pacira released results of its lawsuit against eVenus for patent infringement related to Exparel, which accounts for approximately 80% of the company's revenue [4] - The U S District Court for the District of New Jersey found that Pacira's U S Patent No 11,033,495 is not valid, meaning eVenus was not infringing on anything [4] - Following this news, Pacira's share price fell over 47%, from $22 36 per share on August 8, 2024 to a low of $11 70 per share on August 9, 2024 [5] Legal Actions - Investors who purchased Pacira securities between August 2, 2023 and August 8, 2024 have until March 14, 2025 to file lead plaintiff applications in the securities class action lawsuit [1] - The case is titled Alvarez v Pacira BioSciences, Inc, et al, No 25-cv-00322 [5]